Background:

This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6.

Classification:

Primary antibody

Alternative names:

CYP2A6; CYP2A3; Cytochrome P450 2A6; 1; 4-cineole 2-exo-monooxygenase; CYPIIA6; Coumarin 7-hydroxylase; Cytochrome P450 IIA3; Cytochrome P450(I)

Species reactivity:

Human

Host:

Rabbit

Isotype:

IgG

Immunogen:

The antiserum was produced against synthesized peptide derived from human Cytochrome P450 2A6. AA range:1-50

Concentration:

1 mg/ml

Molecular weight:

56517

Applications:

WB, IF, ELISA

Storage:

-20°C for one year

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com